Demyelinating polyradiculoneuropathy under combined BRAF/MEK inhibitors

Eur J Cancer. 2017 Jun:78:103-104. doi: 10.1016/j.ejca.2017.03.018. Epub 2017 Apr 19.

Authors

Perrine Devic¹, Mona Amini-Adle², Jean-Philippe Camdessanché³, Stéphane Dalle⁴

Affiliations

¹ Department of Neurology, Lyon Sud University Hospital, Hospices Civils de Lyon, France. Electronic address: perrine.devic@chu-lyon.fr.
² Department of Dermatology, Lyon Sud University Hospital, Hospices Civils de Lyon, France; Cancer Research Center of Lyon, INSERM U1052, CNRS UMR5286, Lyon, France. Electronic address: mona.amini-adl@chu-lyon.fr.
³ Department of Neurology, University Hospital of Saint-Etienne, 42055 Saint-Etienne Cedex 02, France. Electronic address: j.philippe.camdessanche@chu-st-etienne.fr.
⁴ Department of Dermatology, Lyon Sud University Hospital, Hospices Civils de Lyon, France; Cancer Research Center of Lyon, INSERM U1052, CNRS UMR5286, Lyon, France; Claude Bernard Lyon 1 University, Lyon, France. Electronic address: stephane.dalle@chu-lyon.fr.

PMID: 28432982
DOI: 10.1016/j.ejca.2017.03.018

No abstract available

Keywords: Chronic inflammatory demyelinating polyneuropathy; Guillain–Barre syndrome; Immunotherapy; Melanoma.

Publication types

Case Reports
Letter

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / administration & dosage
Antineoplastic Combined Chemotherapy Protocols / adverse effects*
Azetidines / administration & dosage
Azetidines / adverse effects
Brain Neoplasms / drug therapy
Demyelinating Diseases / chemically induced*
Demyelinating Diseases / complications
Female
Guillain-Barre Syndrome / chemically induced*
Humans
Indoles / administration & dosage
Indoles / adverse effects
Liver Neoplasms / drug therapy
Liver Neoplasms / secondary
Lung Neoplasms / drug therapy
Lung Neoplasms / secondary
Lymphatic Metastasis
MAP Kinase Kinase Kinases / antagonists & inhibitors
Melanoma / drug therapy*
Melanoma / pathology
Middle Aged
Piperidines / administration & dosage
Piperidines / adverse effects
Polyradiculoneuropathy / chemically induced*
Polyradiculoneuropathy / complications
Protein Kinase Inhibitors / administration & dosage
Protein Kinase Inhibitors / adverse effects*
Proto-Oncogene Proteins B-raf / antagonists & inhibitors
Skin Neoplasms / drug therapy*
Skin Neoplasms / pathology
Sulfonamides / administration & dosage
Sulfonamides / adverse effects
Vemurafenib

Substances

Azetidines
Indoles
Piperidines
Protein Kinase Inhibitors
Sulfonamides
Vemurafenib
BRAF protein, human
Proto-Oncogene Proteins B-raf
MAP Kinase Kinase Kinases
cobimetinib